Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

886 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Behavioural, histological and immunocytochemical consequences following 192 IgG-saporin immunolesions of the basal forebrain cholinergic system.
Perry T, Hodges H, Gray JA. Perry T, et al. Brain Res Bull. 2001 Jan 1;54(1):29-48. doi: 10.1016/s0361-9230(00)00413-5. Brain Res Bull. 2001. PMID: 11226712
Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.
Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH. Perry T, et al. J Neurosci Res. 2003 Jun 1;72(5):603-12. doi: 10.1002/jnr.10611. J Neurosci Res. 2003. PMID: 12749025
A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, Greig NH. Perry T, et al. J Pharmacol Exp Ther. 2002 Mar;300(3):958-66. doi: 10.1124/jpet.300.3.958. J Pharmacol Exp Ther. 2002. PMID: 11861804
Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.
Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Perry T, et al. J Pharmacol Exp Ther. 2002 Sep;302(3):881-8. doi: 10.1124/jpet.102.037481. J Pharmacol Exp Ther. 2002. PMID: 12183643
Behavioural, histochemical and biochemical consequences of selective immunolesions in discrete regions of the basal forebrain cholinergic system.
Torres EM, Perry TA, Blockland A, Wilkinson LS, Wiley RG, Lappi DA, Dunnet SB. Torres EM, et al. Among authors: perry ta. Neuroscience. 1994 Nov;63(1):95-122. doi: 10.1016/0306-4522(94)90010-8. Neuroscience. 1994. PMID: 7898665
A new Alzheimer's disease interventive strategy: GLP-1.
Perry TA, Greig NH. Perry TA, et al. Curr Drug Targets. 2004 Aug;5(6):565-71. doi: 10.2174/1389450043345245. Curr Drug Targets. 2004. PMID: 15270203 Review.
New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists.
Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, Rogers JT, Ovadia H, Lahiri DK. Greig NH, et al. Among authors: perry t. Ann N Y Acad Sci. 2004 Dec;1035:290-315. doi: 10.1196/annals.1332.018. Ann N Y Acad Sci. 2004. PMID: 15681814 Review.
The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease.
Perry T, Greig NH. Perry T, et al. J Alzheimers Dis. 2002 Dec;4(6):487-96. doi: 10.3233/jad-2002-4605. J Alzheimers Dis. 2002. PMID: 12515900 Review.
A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, Lee B, Ingram DK, Lahiri DK. Greig NH, et al. Among authors: perry t. Curr Med Res Opin. 2001;17(3):159-65. doi: 10.1185/0300799039117057. Curr Med Res Opin. 2001. PMID: 11900310 Review.
The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
Greig NH, De Micheli E, Holloway HW, Yu QS, Utsuki T, Perry TA, Brossi A, Ingram DK, Deutsch J, Lahiri DK, Soncrant TT. Greig NH, et al. Among authors: perry ta. Acta Neurol Scand Suppl. 2000;176:74-84. doi: 10.1034/j.1600-0404.2000.00311.x. Acta Neurol Scand Suppl. 2000. PMID: 11261809
886 results
Jump to page
Feedback